

## CLAIMS

1. An agent comprising a phosphorylated dextran as an active ingredient, and having an immunopotentiating activity.
- 5 2. The agent of claim 1, wherein the agent is a B cell-specific mitogen.
3. The agent of claim 1, wherein the immunopotentiating activity is a blastogenic activity.
4. The agent of claim 1, wherein the immunopotentiating activity is an activity of inducing interferon  $\gamma$  (IFN- $\gamma$ ) or interleukin 10 (IL-10).
- 10 5. A pharmaceutical composition for preventing, improving, or treating infectious diseases, colitis, or allergic diseases, wherein the composition comprises a phosphorylated dextran as an active ingredient.
6. A food composition for preventing or improving infectious diseases, colitis, or allergic diseases, wherein the composition comprises a phosphorylated dextran as an active ingredient.
- 15 7. A method for immunopotentiating a cell, which comprises the step of contacting the cell with a phosphorylated dextran.
8. The method of claim 7, wherein the immunopotentialization is blastogenesis.
- 20 9. The method of claim 7, wherein the immunopotentialization is the induction of interferon  $\gamma$  (IFN- $\gamma$ ) or interleukin 10 (IL-10).
10. The method of any one of claims 7 to 9, wherein the cells are derived from spleen cells or dendritic cells.
- 25 11. A method for producing a phosphorylated dextran, which comprises the step of reacting a dextran with polyphosphoric acid in a formaldehyde solution.
12. The method of claim 11, wherein a dextran and polyphosphoric acid are reacted under heat.
- 30 13. The composition of claim 5 or 6, wherein the phosphorylated dextran is produced by a method comprising the following steps of:
  - (a) reacting a dextran with a phosphate buffer under heat;
  - (b) freeze-drying the reaction solution of step (a); and
  - (c) heating the freeze-dried sample of step (b) at 100-160°C for 24
- 35 hours.